SECAUCUS, N.J. — March 12, 2026
Pierre Fabre Pharmaceuticals announced that the U.S. Food and Drug Administration has agreed to hold a Type A regulatory meeting regarding the Biologics License Application (BLA) for tabelecleucel, an investigational allogeneic T-cell immunotherapy intended to treat relapsed or refractory Epstein-Barr virus–positive post-transplant lymphoproliferative disease (EBV+ PTLD). The meeting represents an important step in ongoing regulatory discussions following a Complete Response Letter issued by the FDA in January 2026, which requested additional clarification before approval could be considered.
The Type A meeting process enables companies and regulators to address critical issues related to drug applications and identify a potential path forward for regulatory approval. Pierre Fabre Pharmaceuticals plans to use the meeting to discuss clinical data, trial design considerations, and regulatory expectations associated with the tabelecleucel BLA submission.
Advancing Regulatory Dialogue for Tabelecleucel
Tabelecleucel, also known as tab-cel, is a first-in-class allogeneic T-cell immunotherapy designed to target and eliminate Epstein-Barr virus-infected B cells, which drive the development of EBV-positive post-transplant lymphoproliferative disease. EBV+ PTLD is a rare and potentially life-threatening complication that can occur following organ or stem-cell transplantation, particularly in patients with compromised immune systems.
The therapy has already generated significant interest within the oncology and transplant communities because there are currently no FDA-approved therapies specifically indicated for this disease in the United States.
The tabelecleucel development program includes results from the Phase 3 ALLELE clinical study, which evaluated the therapy in patients whose disease progressed following prior treatments such as rituximab-based therapy. Clinical findings from this program and supportive datasets from hundreds of treated patients form the foundation of the ongoing BLA review.
By requesting and securing a Type A meeting, Pierre Fabre aims to work closely with the FDA to resolve regulatory questions and determine the next steps needed for potential resubmission or accelerated approval pathways.
Addressing Regulatory Feedback After FDA Complete Response
The FDA issued a Complete Response Letter (CRL) on January 9, 2026, indicating that the agency was unable to approve the tabelecleucel application in its current form and requesting further discussion on aspects of the clinical data and trial analysis.
In response, Pierre Fabre submitted a Type A meeting request on March 2, 2026 to address the agency’s concerns and present additional data supporting the therapy’s efficacy and safety.
Type A meetings are typically granted when sponsors need to resolve critical regulatory obstacles that could delay drug approval, allowing both parties to discuss key scientific and regulatory issues within a structured framework. During the meeting, Pierre Fabre plans to present updated evidence from the tabelecleucel clinical development program and discuss how the existing data may support accelerated approval pathways for patients with limited treatment options.
Company leadership emphasized that the goal of the meeting is to align with FDA regulators on the appropriate next steps for the therapy’s development and potential approval in the United States.
Expanding Access to Novel T-Cell Immunotherapies
Tabelecleucel represents a novel therapeutic approach using donor-derived T-cells specifically trained to recognize and eliminate EBV-infected cells. By targeting the underlying viral driver of the disease, the therapy aims to provide a precision immunotherapy strategy for patients who have exhausted standard treatment options.
The therapy has already received regulatory approval in Europe under the brand name Ebvallo, demonstrating the potential clinical benefit of the treatment for patients with EBV+ PTLD. However, approval in the United States remains pending as regulators review additional clinical and manufacturing data.
Pierre Fabre Pharmaceuticals assumed responsibility for the global clinical development and regulatory submission of tabelecleucel after the biologics license application was transferred from its original developer, Atara Biotherapeutics.
If approved by the FDA, tabelecleucel could become the first approved therapy in the United States specifically targeting EBV-positive post-transplant lymphoproliferative disease, providing a much-needed treatment option for transplant recipients facing this rare cancer.
As regulatory discussions continue, the upcoming Type A meeting will play a critical role in determining the future regulatory pathway and potential availability of this innovative cell-based immunotherapy for patients with limited treatment alternatives.
z
Source: Pierre Fabre Pharmaceuticals press release
